Dov Goldstein's Trading History
| BIOABioAge Labs, Inc. | Apr 24, 2026 | CFO | Uninformative Buy | 15.51K | $214.70K | |
| COYACoya Therapeutics, Inc. | Aug 19, 2025 | Director | Uninformative Buy | 19.14K | $99.48K | |
| NBSENeuBase Therapeutics | Jun 21, 2021 | ― | Informative Buy | 38.00K | $11.34K | |
| ADMAADMA Biologics | Mar 03, 2020 | Director | Uninformative Buy | ― | $85.58K | |
| ESPREsperion | Jun 08, 2018 | ― | Uninformative Buy | 214.10K | $149.46 | |
| MLNTQMelinta Therapeutics | Mar 09, 2017 | ― | Informative Sell | 532.00K | $241.25K | |
| LOXOLoxo Oncology | Apr 03, 2015 | ― | Informative Buy | 278.60K | $825.62M | |
| DRTXDurata | Jul 25, 2012 | ― | Uninformative Buy | ― | ― | |
| GANXGain Therapeutics | ― | Director | ― | ― |
You May Also Like
Dov Goldstein insider profile FAQ
What is the percentage of profitable transactions made by Dov Goldstein?
The percentage of profitable transactions made by Dov Goldstein is 64%.
What is the average return per transaction made by Dov Goldstein?
The average return per transaction made by Dov Goldstein is 10.70%.
What stocks does Dov Goldstein hold?
Dov Goldstein holds: GANX, NBSE, LOXO, COYA, BIOA, MLNTQ, ESPR, ADMA, DRTX stocks.
What was Dov Goldstein's most profitable transaction?
Dov Goldstein’s most profitable transaction was an Informative Buy of LOXO stock on April 3, 2015. The return on the trade was 137.50%.
What is Dov Goldstein's role in Gain Therapeutics?
Dov Goldstein's role in Gain Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.